TheEdgeResearch
Home / Stocks / OZYMF

Strategic Partners A/S (OZYMF)

OTC Healthcare Biotechnology
$90.00 ▲ +0.00%
Market Cap
$3.7M
Sector
Healthcare
Industry
Biotechnology
Beta
0.27
52-Wk Range
0.09-90
CEO
Jakob Færch Bendtsen
Country
DK
Currency
USD

Strategic Partners A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, CR, DK. The stock last traded at $90.00, up 0.00% on the session, giving a market capitalisation of $3.7M. On trailing twelve-month figures it carries a trailing P/E of 21.68, a net margin of 329.3%. Its beta of 0.27 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
21.68
Price / Sales
70.77
Price / Book
1.50
EV / EBITDA
-15.00
Gross margin
75.6%
Operating margin
-470.7%
Net margin
329.3%
Return on equity
Debt / equity
0.00
Current ratio
23.55
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2019-07-16
Headquarters
Copenhagen, CR, DK
About Strategic Partners A/S

Initially operating as Orphazyme A/S, the company adopted its current name, Strategic Partners A/S, in October 2024. Established in 2009, this Danish entity is headquartered in Herlev. Historically, its primary focus was on biotechnology; however, it presently conducts no significant business operations.

Comparable companies

Strategic Partners A/S is most often compared with the following Healthcare names:

EVLOHLUNNNLXPXMDQBIOSDCCQTRVNUSMJVAXXXSNX
More research on OZYMF
OZYMF technical analysis OZYMF TheEdge Score Compare against peers
Open full interactive analysis & DCF →